Biohaven licenses IgG degrader portfolio to Ono for Japan and select Asian markets

What's the deal? Biohaven announced on 8 October 2026 an exclusive licensing agreement with Ono PharmaceuticalDealroom has a profile for this one. Try Dealroom → covering its extracellular IgG degraders — a new class of therapy that breaks down disease-causing antibodies — in Japan, South Korea, Taiwan and the ASEAN member states. The licence covers lead candidate BHV-1300, which is in Phase 3 for Graves' disease (an autoimmune thyroid condition), along with BHV-1310, BHV-1320 and certain next-generation follow-on degraders. Biohaven receives US$80 million upfront, up to US$100 million in near-term payments including a US$20 million milestone expected within a year, plus tiered royalties on future sales.

Why it matters: The deal gives Ono exclusive rights to a promising new drug class across several of Asia's largest markets while paying Biohaven for part of its pipeline. Biohaven retains rights in the rest of the world, so the arrangement funds its development through upfront cash and a regional commercial partner ahead of a planned global launch of BHV-1300.

Read more: PR Newswire, 8 October 2026 · Ono Pharmaceutical, 8 October 2026